Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MD Medical Group MDMG Admission to Trading



  MD Medical Group (MDMG) - Admission to Trading

RNS Number : 9508O
MD Medical Group Investments PLC
17 October 2012
 



THIS  PRESS  RELEASE  AND  THE   INFORMATION  CONTAINED  HEREIN  IS  NOT   FOR 
PUBLICATION, DISTRIBUTION OR RELEASE IN, OR INTO, DIRECTLY OR INDIRECTLY,  THE 
UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS),  CANADA, 
JAPAN OR AUSTRALIA  OR TO ANY  OTHER JURISDICTION WHERE  SUCH AN  ANNOUNCEMENT 
WOULD BE UNLAWFUL.  THE INFORMATION  CONTAINED HEREIN DOES  NOT CONSTITUTE  AN 
OFFER OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

 

This press release is, for UK regulatory purposes, an advertisement and not  a 
prospectus and investors should not  subscribe for or purchase any  securities 
referred to in this press  release except on the  basis of information in  the 
prospectus published by MD Medical  Group Investments Plc. This press  release 
does not constitute or form part of any offer or invitation to sell or  issue, 
or any solicitation of any offer to  purchase or subscribe for, any shares  or 
other securities of MD Medical Group Investments Plc, nor shall any part of it
nor the fact of its  distribution form part of or  be relied on in  connection 
with any  contract  or  investment  decision relating  thereto,  nor  does  it 
constitute a  recommendation  regarding the  securities  of MD  Medical  Group 
Investments Plc.

 

                

                               MD MEDICAL GROUP

       ADMISSION TO TRADING AND COMMENCEMENT OF UNCONDITIONAL DEALINGS

                                       

17 October 2012 - MD Medical Group Investments Plc ("MD Medical Group" -  LSE: 
MDMG), Russia's leading provider of private women's and children's healthcare,
today announces that  its global  depositary receipts ("GDRs"),  with one  GDR 
representing an interest  in one  ordinary share,  have been  admitted to  the 
Official List of  the UK  Listing Authority and  to trading  on the  regulated 
market of the London Stock Exchange plc.

 

Unconditional dealings in MD Medical Group  shares commenced at 8.00 am  today 
under the ticker symbol "MDMG".

 

MD Medical Group further announces that  it chooses the United Kingdom as  its 
Home State. The decision is made  pursuant to Article 2.1(i)(ii) of  Directive 
2004/109/EC of the European  Parliament and of the  Council, 15 December  2004 
(the Transparency Directive). This announcement is made in accordance with the
United Kingdom Financial Services Authority Disclosure and Transparency Rules,
DTR 6.4.2R. It is  made in compliance with  the minimum standards required  in 
DTR 6.3.

 

 

For further information, contact:

 

MD Medical Group

Andrey Braginskiy (Investors)

Tel: +7 985 211 7478

ir@mospmc.ru

 

Anastasia Anichenkova (Media)

Tel: +7 495 332 6670 / +7 916 661 6242

a.anichenkova@mospmc.ru

 

M:Communications

Tom Blackwell / Anna Yarmarkova - Moscow

Tel: +7 495 363 2846

mdmg@mcomgroup.com

 

Sarah Macleod / Mary-Jane Elliott - London

Tel: +44 20 7920 2300

mdmg@mcomgroup.com

 

 

 

 

IMPORTANT NOTICE

 

This press-release does  not constitute  or form part  of, and  should not  be 
construed as, an offer of securities to the public in the United Kingdom,  nor 
is it intended to be  an inducement to engage  in investment activity for  the 
purpose of  Section 21  of the  Financial Services  and Markets  Act 2000  (as 
amended) of the United Kingdom  ("FSMA"). Consequently, this press-release  is 
only being distributed to and is directed only at (i) persons who are  outside 
the United Kingdom or (ii) persons who have professional experience in matters
relating to investments  falling within the  meaning of Article  19(5) of  the 
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005  (the 
"FP Order"), (iii) high net worth entities falling within Article 49(2)(a)-(d)
of the FP Order and (iv) other persons to whom it may lawfully be communicated
(all such  persons together  being referred  to as  "relevant persons").   Any 
investment activity to which this press-release relates will only be available
to, and will only be engaged with, relevant persons.  Any person who is not  a 
relevant person  should  not act  or  rely on  this  document or  any  of  its 
contents.

 

This press-release is  not an  offer to  sell nor  a solicitation  to buy  any 
securities  nor  a  prospectus  for   the  purposes  of  applicable   measures 
implementing EU Directive 2003/71/EC  as may be amended  from time to time.  A 
prospectus has been prepared and is available to the public in accordance with
Directive 2003/71/EC (together  with any applicable  implementing measures  in 
any Member State, the "Prospectus Directive"). Investors should not  subscribe 
for or purchase any securities referred to in this press release except on the
basis of the information  contained in the prospectus  to be published by  the 
Company in due  course relating to  the securities. Copies  of the  prospectus 
will, following  publication,  be  available  from  the  Company's  registered 
office.

 

The information contained  herein is  not for publication  or distribution  to 
persons in the United States. Any securities referred to herein have not  been 
and will not be registered under the  U.S. Securities Act, or the laws of  any 
state of the United States, and may  not be offered or sold within the  United 
States without  registration  under  the  Securities Act  or  pursuant  to  an 
available exemption  thereunder. Neither  this  document nor  the  information 
contained herein constitutes an offer to sell or the solicitation of an  offer 
to buy any securities  in the United  States. The Company  does not intend  to 
register any portion of the proposed offering in the United States or  conduct 
a public offering of securities in the United States.

 

This press-release do not  constitute a public offer  or advertisement of  any 
securities in  the Russian  Federation, an  offer, or  an invitation  to  make 
offers, to purchase, sell, exchange or transfer any securities in the  Russian 
Federation or to the benefit  of any Russian person  and do not constitute  an 
"advertisement" or  "offering" of  the securities  in the  Russian  Federation 
within the meaning of  Russian securities laws  and must not  be passed on  to 
third  parties  or  otherwise  be  made  publicly  available  in  the  Russian 
Federation. No prospectus will be registered with respect to these  securities 
in the  Russian Federation  and  the securities  referred  to herein  are  not 
intended  for,  "offering",  "placement"  or  "circulation"  in  the   Russian 
Federation unless otherwise permitted under Russian law.

 

The information contained herein does not  constitute an offer to sell or  the 
solicitation of an offer to buy, nor shall there be any sale of the securities
referred to herein in  any jurisdiction in which  such offer, solicitation  or 
sale would be unlawful prior  to registration, exemption from registration  or 
qualification under the securities laws of any such jurisdiction.

 

Some of the information in this press release may contain projections or other
forward‐looking statements  regarding future  events.  The Company  wishes  to 
caution you that these statements are only predictions and that actual  events 
or results may differ materially. The Company does not intend to update  these 
statements to reflect events and circumstances occurring after the date hereof
or to reflect the occurrence of unanticipated events.

 

Not for publication, distribution or release  in the United States of  America 
(including its territories and possessions), Canada, Japan or Australia.

 

In connection with the offering, Deutsche Bank AG, London Branch or any  agent 
or other person acting on  its behalf may over-allot GDRs  up to a maximum  of 
3,380,624 additional GDRs  or effect other  stabilisation transactions with  a 
view to supporting the market  price of the GDRs at  a level higher than  that 
which  might  otherwise  prevail  in  the  open  market.  Such   stabilisation 
activities may be effected on any securities market, over-the-counter  market, 
stock exchange  or otherwise  and may  be undertaken  at any  time during  the 
period commencing  on the  date of  the announcement  of the  offer price  and 
ending no later than  30 calendar days thereafter.  However, there will be  no 
obligation on Deutsche Bank AG, London Branch  or any of its agents to  effect 
stabilising transactions,  and  there can  be  no assurance  that  stabilising 
transactions will  be  undertaken.  Such stabilising,  if  commenced,  may  be 
discontinued at any time  without prior notice. In  no event will measures  be 
taken to stabilise the market price of the GDRs above the offer price.

 

Save as required by  law or regulation, Deutsche  Bank AG, London Branch  does 
not  intend  to  disclose  the  extent  of  any  over-allotments  made  and/or 
stabilisation transactions conducted in relation to the offering.

                     This information is provided by RNS
           The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDGLBBBGDR -0- Oct/17/2012 17:20 GMT
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement